Tropical Diseases

About Tropical Diseases

Tropical diseases are diseases that are indigenous to subtropical or tropical regions and are less prevalent in temperate climates which are subject to seasonal changes. Whereas the term covers all communicable and non-communicable illnesses, genetic disorders, and conditions caused by nutritional deficiencies or environmental factors, we mostly understand tropical diseases to be of infectious nature. This is especially true, since rising migration and globalization have led to a faster spread of such diseases. 

Besides socio-economic factors, high infection rates are largely attributed to the availability of many animal reservoirs for vector-borne transmission (e.g., bats, mosquitoes, flies), and a hot and moist climate accelerating replication of pathogens. 

The WHO and other health programs established research institutions to study neglected infectious diseases, as they disproportionally affect low-income and marginalized regions in Africa, Asia, Central America, and South America, to provide monitoring-, diagnosis-, treatment-, and prevention tools to combat these diseases. 

Our variety of peptide formats provide many necessary tools to monitor immune response of high-risk patients, epitope discovery, immunodominant antigen identification for development of vaccines, treatment solutions and diagnostics. Our peptides range from research-use-only to clinical formats that meet authority regulations. 

List of common Tropical Diseases 

The most commonly studied tropical diseases, for which we provide peptide tools, include: 

JPT's peptide formats

Cellular Immune Response

PepMix Peptide Pools 
  • Antigen specific stimulation of T-cells
  • Immune monitoring of high-risk patients
  • Qualification of immunodominant antigens
  • Validating clinical T-cell assays

Custom PepMix Peptide Pools for your specific needs!

  • T-cell assays in
  • High-throughput T-cell epitope discovery
  • Monitoring of cellular immune response
  • Clinical trials

We are the experts for peptide synthesis with highest quality optimized for many applications. Our peptide synthesis service has a very high success rate (over 99%) as we optimize the appropriate peptide synthesis method for each peptide.
If you would like to order a quality peptide synthesis using regulated processes, choose JPT!

Humoral Immune Response

Peptide Microarrays 
  • Immune monitoring of humoral responses
  • Profiling of specific samples or antibodies
  • Evaluation of co-infection
  • Detection of epitopes and epitope spreading

You define content and layout, we provide economic and fast production in our regulated clean-room environment. We also offer our assay and analysis service using your samples with your tailored peptide microarray.

Our tailored Peptide ELISA plates are offered as stand alone service for mapping of epitopes and definition of protein interaction sites or as validation assay to confirm results obtained with JPT’s peptide microarrays. 

  • Immune monitoring of humoral responses
  • epitope discovery and epitope mapping
  • SPOT synthesis is a technique for custom synthesis of hundreds of membrane peptides in parallel
  • fast and economical

Clinical Peptides

Clinical Peptides
JPT’s Clinical Peptides product lines Clinical Grade and ISO Plus are produced in production environments that are regulated by an enhanced ISO 9001:2015 quality management system for the stringent product requirements of immunotherapy as well as vaccine and drug development. Depending on the specifics of the immunotherapy concept to be applied, the resulting products have been shown to be applicable in clinical applications.


Ebolavirus Disease 

Ebola virus disease or ‘Ebola fever’ is an often lethal hemorrhagic fever. Occasionally, Ebolaviruses cause disease outbreaks, mostly in African countries. These viruses infect humans and other primates and are likely to spread from bats to humans through contact with blood, body fluids, and tissues of infected animals. 

Ebolaviruses belong to the family of Filoviridae. Four of the six known ebolavirus species cause disease in humans: Sudan ebolavirus, Bundibugyo ebolavirus, Tai Forest ebolavirus, and Zaire ebolavirus, with the latter having the highest mortality rate (83% on average). The 2014-2016 Ebola outbreaks in West Africa were caused by a Zaire ebolavirus strain and were considered among the most severe to date in terms of mortality. All ebolaviruses are in risk group 4 (RG4) of human and animal pathogens according to the WHO. 

About Ebolavirus 

Ebolaviruses are single-stranded RNA (ssRNA) viruses. Their genome codes for a number of proteins that are potentially relevant to the human immune response. These include, for example, a nucleoprotein (NP), a spike glycoprotein (GP), a polymerase cofactor, a transcription activator, and an RNA-dependent RNA polymerase. 

If you are interested in viruses causing hemorrhagic fever, you may also be interested in the Crimean-Congo hemorrhagic fever virus (CCHFV), tools which will soon add to our catalog. It belongs to the genus of Orthonairoviruses and is tick-borne. It is also called the ‘Asian ebolavirus’, because the clinical picture in humans resembles ebolavirus disease and the underlying disease mechanisms appear very similar. 

JPT's Peptide Tools to Study Ebola


About M. tuberculosis 

Mycobacterium tuberculosis belongs to the family of Mycobacteriaceae and is the main cause for tuberculosis (TB). In most individuals M. tuberculosis does not cause acute clinical disease but remains a latent tuberculosis infection (LTBI). Nevertheless, TB is still a severe and potentially lethal infection of all times causing about 1.5 million deaths annually.

Unfortunately, TB vaccines provide incomplete protection, but appear to be able to prevent the most severe clinical courses. Improving TB vaccines is the focus of ongoing research studies worldwide. In addition a range of immunological TB diagnostics tests are available including both established clinical tests and experimental approaches. 

Current Research

Both the WHO and the United Nations defined global TB goals, to reduce infection rates and even to eradicate the epidemics by 2030, respectively. 

One of these goals is the development of a new vaccine that overcomes the challenges of the current employed vaccine relying on M. bovis bacilli Calmette Guérin. More than a dozen TB vaccine candidates are under active clinical evaluation to prevent infection, disease, and recurrence. However, a reoccurring issue is the lack of reliable biomarkers to assess a vaccine’s efficacy. Furthermore, to monitor infections, affordable rapid-tests are being expanded. In 2021 the WHO issued a recommendation to improve access to testing and summarized innovations that are being investigated up to date. 

We provide an extensive and continuously updated peptide catalog covering many antigens from Ag85 to ESAT-6 of secreted proteins allowing screening and monitoring humoral and cellular immune responses against these major TB antigens. 

 JPT's Peptide Tools to Study M. tuberculosis


About Zika Virus and other Flaviviruses 

Zika virus (ZIKV) belongs to the flaviviruses such as dengue virus, West Nile virus, yellow fever virus, Saint Louis encephalitis virus and tick-borne encephalitis virus. Flaviviruses carry a positive-sense, single-stranded RNA and most flaviviruses are transmitted by the bite from an infected arthropod (mosquito or tick). We offer specific Zika virus peptides, Zika peptide pools and Zika peptide microarrays (ZIKV peptides, ZIKV peptide pools, ZIKV peptide microarrays).

product icon zika 1zu2

Zika Virus: 

  • Transmitted by the mosquitoes A. aegypti and A. albopictus 
  • Was first isolated in 1947 from the Zika Forest of Uganda 
  • From 2007 the virus spread across the Pacific Ocean to South America, leading to the Zika virus epidemic 
  • Zika virus causes Zika fever or Zika virus disease 
  • Usually shows no or only mild symptoms 
  • Zika can also spread from a pregnant women to the fetuses 
  • Causes microcephaly, severe brain malformations, and other birth defects in unborn children 

 JPT's Peptide Tools to Study Zika Virus




  • Ebola Vaccine-induced Protection in Non-human Primates correlates with Antibody Specificity and Fc-mediated Effects
    Meyer et al., SciTranslMed (2021) - PMID: 34261800 
  • Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine
    Blaney et al., PLOS Pathogens (2013) - PMID: 2373747
  • Combined plasma cell-free DNA detection and IFNγ/TNF-α dual fluorospot assays for diagnosing active tuberculosis
    Kim et al., Research Square (2022)
  • Rekombinowane cząstki wirusopodobne jako potencjalne antygeny szczepionkowe przeciwko wirusowi Zika
    Brzuska et al., Dissertation (2022) 
  • Identification of Naturally Processed Zika Virus Peptides by Mass Spectrometry and Validation of T cell Recall Responses in Zika Convalescent Subjects
    Crooke et al., PLoS One (2021) 
  • Generation of Zika Virus-Specific T Cells from Seropositive and Virus-Naïve Donors for Potential Use as an Autologous or "Off-the-Shelf" Immunotherapeutic
    Hanajiri et al, Cytotherapy (2019) 
  • Vaccine Protection Against Zika Virus from Brazil
    Larocca et al., Nature (2016) PMID: 27355570 
  • Protective Efficacy of Multiple Vaccine Platforms Against Zika Virus Challenge in Rhesus Monkeys
    Abbink et al., Science (2016) PMID: 27492477 
  • Mapping the Sequence Space of ZIKA and Related Viruses: High-Content Peptide Libraries for Immune Monitoring
    Von Hoegen et al., Conference Poster (2016) 
  • Identification of Naturally Processed Zika Virus Peptides by Mass Spectrometry and Validation of Memory T Cell Recall Responses in Zika Convalescent Subjects
    Crooke et al., PLoS One, (2021) 
  • mRNA Vaccine Protects against Zika Virus
    Medina-Magües et al., Vaccines, (2021) 
  • Optimization of Zika DNA Vaccine by Delivery Systems
    Yun Ha Lee et al., Virology, (2021)

Application Notes

Check our list of products, click and go.

Get a quote